Authors
Zotov A.S.1, Pidanov O.Y.2, Osmanov I.S.1, Korolev S.V.1, Gorbacheva E.S.1, Drakina O.V.3, Troitsky A.V.1, Khabazov R.I.1
1 Сardiac Surgery Department of Federal Research and Clinical Center, Moscow
2 I.V. Davydovsky Clinical Hospital, Moscow
3 I.M. Sechenov First Moscow State Medical University, Moscow
Abstract
Atrial fibrillation is the most common cardiac arrhythmia observed in clinical practice. Despite advances in diagnostic methods and treatment, atrial fibrillation remains one of the general causes of cardiovascular mortality and morbidity. In recent times the prevalence of atrial fibrillation has been growing, due to improved diagnosis, aging population and an increase the prevalence of diseases and risk factors leading to the development of arrhythmia.
Atrial fibrillation and heart failure are often diagnosed together. The combination of these diseases can raise the risk of stroke, the number of hospitalizations and mortality from all cardiovascular causes.
Pharmacological treatment of atrial fibrillation is a challenging task, especially in patients with a reduced ejection fraction, because most antiarrhythmic drugs have a negative inotropic effect. Currently, the focus in the treatment of arrhythmia is shifted towards the rhythm control strategy, especially to catheter ablation. Several studies have demonstrated that pulmonary vein ablation can improve outcomes and prognosis.
Keywords: atrial fibrillation, heart failure, catheter ablation, thoracoscopic ablation, pulmonary veins ablation.
References
1. Kotecha D, Chudasama R, Lane DA, et al. Atrial fibrillation and heart failure due to reduced versus preserved ejection fraction: a systematic review and meta-analysis of death and adverse outcomes. Int J Cardiol. 2016; 203: 660-6.
2. Hindricks G, Potpara T, Dagres N, et al. 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European association for Cardio-Thoracic surgery (EACTS). Eur Heart J. 2021; 42: 373-498.
3. Gorenek B, Halvorsen S, Kudaiberdieva G, et al. Atrial fibrillation in acute heart failure: a position statement from the Acute Cardiovascular Care Association and European Heart Rhythm Association of the European Society of Cardiology. Eur Heart J Acute Cardiovasc Care. 2020; 9: 348-57.
4. Santhanakrishnan R, Wang N, Larson MG, et al. Atrial fibrillation begets heart failure and vice versa: temporal associations and differences in preserved versus reduced ejection fraction. Circulation. 2016; 133: 484-92.
5. Wang TJ, Larson MG, Levy D, et al. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham heart study. Circulation. 2003; 107: 2920-5.
6. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016; 37: 2129-200.
7. Rienstra M, Hobbelt AH, Alings M, et al. Targeted therapy of underlying conditions improves sinus rhythm maintenance in patients with persistent atrial fibrillation: results of the RACE 3 trial. Eur Heart J. 2018; 39: 2987-96.
8. Rienstra M, Van Gelder IC, Van den Berg MP, et al. A comparison of low versus high heart rate in patients with atrial fibrillation and advanced chronic heart failure: effects on clinical profile, neurohormones and survival. Int J Cardiol. 2006;109: 95-100.
9. Pathak RK, Middeldorp ME, Meredith M, et al. Long-term effect of goal-directed weight management in an atrial fibrillation cohort: a long-term follow-up study (LEGACY). J Am Coll Cardiol. 2015; 65: 2159-69.
10. Pathak RK, Elliott A, Middeldorp ME, et al. Impact of cardiorespiratory fitness on arrhythmia recurrence in obese individuals with atrial fibrillation: the CARDIO-FIT study. J Am Coll Cardiol. 2015; 66: 985-96.
11. Pathak RK, Middeldorp ME, Lau DH, et al. Aggressive risk factor reduction study for atrial fibrillation and implications for the outcome of ablation: the ARREST-AF cohort study. J Am Coll Cardiol. 2014; 64: 2222-31.
12. Goette A, Kalman JM, Aguinaga L, et al. EHRA/HRS/APHRS/SOLAECE expert consensus on atrial cardiomyopathies: definition, characterization, and clinical implication. Europace. 2016; 18: 1455-90.
13. Deedwania PC, Lardizabal JA. Atrial fibrillation in heart failure: a comprehensive review. Am J Med. 2010; 123: 198-204.
14. Nerheim P, Birger-Botkin S, Piracha L, et al. Heart failure and sudden death in patients with tachycardia-induced cardiomyopathy and recurrent tachycardia. Circulation. 2004; 110: 247-52.
15. Di Biase L, Mohanty P, Mohanty S, et al. Ablation versus amiodarone for treatment of persistent atrial fibrillation in patients with congestive heart failure and an implanted device: results from the AATAC multicenter randomized trial. Circulation. 2016; 133: 1637-44.
16. Delgado V, Bax JJ. Atrial functional mitral regurgitation: from mitral annulus dilatation to insufficient leaflet remodeling. Circ Cardiovasc Imaging. 2017; 10.
17. Mulder BA, Rienstra M., Van Gelder I.C., et al. Update on management of atrial fibrillation in heart failure: a focus on ablation. Heart. 2021; 0: 1-7. doi:10.1136/heartjnl-2020-318081.
18. Khan MN, Jaïs P, Cummings J, et al. Pulmonary-vein isolation for atrial fibrillation in patients with heart failure. N Engl J Med. 2008; 359: 1778-85.
19. Marrouche NF, Brachmann J, Andresen D, et al. Catheter ablation for atrial fibrillation with heart failure. N Engl J Med. 2018; 378: 417-27.
20. MacDonald MR, Connelly DT, Hawkins NM, et al. Radiofrequency ablation for persistent atrial fibrillation in patients with advanced heart failure and severe left ventricular systolic dysfunction: a randomised controlled trial. Heart. 2011; 97: 740-7.
21. Jones DG, Haldar SK, Hussain W, et al. A randomized trial to assess catheter ablation versus rate control in the management of persistent atrial fibrillation in heart failure. J Am Coll Cardiol. 2013; 61: 1894-903.
22. Hunter RJ, Berriman TJ, Diab I, et al. A randomized controlled trial of catheter ablation versus medical treatment of atrial fibrillation in heart failure (the CAMTAF trial). Circ Arrhythm Electrophysiol. 2014; 7: 31-8.
23. Prabhu S, Taylor AJ, Costello BT, et al. Catheter ablation versus medical rate control in atrial fibrillation and systolic dysfunction: the CAMERA-MRI study. J Am Coll Cardiol. 2017; 70: 1949-61.
24. Chen S, Pürerfellner H, Meyer C, et al. Rhythm control for patients with atrial fibrillation complicated with heart failure in the contemporary era of catheter ablation: a stratified pooled analysis of randomized data. Eur Heart J. 2020; 41: 2863-73.
25. Torp-Pedersen C, Møller M, Bloch-Thomsen PE, et al. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish investigations of arrhythmia and mortality on dofetilide Study Group. N Engl J Med.1999; 341: 857-65.
26. Hagens VE, Van Veldhuisen DJ, Kamp O, et al. Effect of rate and rhythm control on left ventricular function and cardiac dimensions in patients with persistent atrial fibrillation: results from the RAte control versus electrical cardioversion for persistent atrial fibrillation (race) study. Heart Rhythm. 2005; 2: 19-24.
27. Freudenberger RS, Wilson AC, Kostis JB, et al. Comparison of rate versus rhythm control for atrial fibrillation in patients with left ventricular dysfunction (from the AFFIRM study). Am J Cardiol. 2007; 100: 247-52.
28. Roy D, Talajic M, Nattel S, et al. Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med. 2008; 358: 2667-77.
29. Shelton RJ, Clark AL, Goode K, et al. A randomised, controlled study of rate versus rhythm control in patients with chronic atrial fibrillation and heart failure: (CAFE-II study). Heart. 2009; 95: 924-30.
30. Al-Jazairi MIH, Nguyen B-O, De With RR, et al. Antiarrhythmic drugs in patients with early persistent atrial fibrillation and heart failure: results of the race 3 study. Europace. 2021. doi:10.1093/europace/euab062.
31. Asad ZUA, Yousif A, Khan MS, et al. Catheter ablation versus medical therapy for atrial fibrillation: a systematic review and meta-analysis of randomized controlled trials. Circ Arrhythm Electrophysiol. 2019; 12: e007414.
32. Kheiri B, Osman M, Abdalla A, et al. Catheter ablation of atrial fibrillation with heart failure: an updated meta-analysis of randomized trials. Int J Cardiol. 2018; 269: 170-3.
33. Sohns C, Zintl K, Zhao Y, et al. Impact of left ventricular function and heart failure symptoms on outcomes post ablation of atrial fibrillation in heart failure: CASTLE-AF trial. Circ Arrhythm Electrophysiol. 2020; 13: e008461.
34. Brachmann J, Sohns C, Andresen D, et al. Atrial Fibrillation Burden and Clinical Outcomes in Heart Failure: The CASTLE-AF Trial. JACC Clin Electrophysiol. 2021; 7: 594-603.
35. Packer DL, Piccini JP, Monahan KH, et al. Ablation versus drug therapy for atrial fibrillation in heart failure: results from the CABANA trial. Circulation. 2021; 143: 1377-90.
36. Packer DL, Mark DB, Robb RA, et al. Effect of catheter ablation vs antiarrhythmic drug therapy on mortality, stroke, bleeding, and cardiac arrest among patients with atrial fibrillation: the CABANA randomized clinical trial. JAMA. 2019; 321: 1261-74.
37. Kirchhof P, Camm AJ, Goette A, et al. Early Rhythm-Control therapy in patients with atrial fibrillation. N Engl J Med. 2020; 383: 1305.16.
38. Mulder BA, van Veldhuisen DJ, Rienstra M. What should the C (’congestive heart failure’) represent in the CHA2DS2-VASc score? Eur J Heart Fail. 2020; 22: 1294-7.
39. Verma A, Jiang C-yang, Betts TR, et al. Approaches to catheter ablation for persistent atrial fibrillation. N Engl J Med. 2015; 372: 1812-22.
40. Winkle RA, Mead RH, Engel G, et al. High-power, short-duration atrial fibrillation ablations using contact force sensing catheters: outcomes and predictors of success including posterior wall isolation. Heart Rhythm. 2020; 17: 1223-31.
41. Mulder BA, Luermans JGLM, Hindricks G, et al. Innovations and paradigm shifts in atrial fibrillation ablation. Europace. 2021; 23: ii23-7.
42. Al-Jazairi MIH, Rienstra M, Klinkenberg TJ, et al. Hybrid atrial fibrillation ablation in patients with persistent atrial fibrillation or failed catheter ablation. Neth Heart J. 2019; 27: 142-51.
43. Pison L, La Meir M, van Opstal J, et al. Hybrid thoracoscopic surgical and transvenous catheter ablation of atrial fibrillation. J Am Coll Cardiol. 2012; 60: 54-61.
44. DeLurgio DB, Ferguson E, Gill J, et al. Convergence of epicardial and endocardial rf ablation for the treatment of symptomatic persistent AF (CONVERGE trial): rationale and design. Am Heart J. 2020; 224: 182-91.
45. Noseworthy PA, Van Houten HK, Gersh BJ, et al. Generalizability of the CASTLE-AF trial: catheter ablation for patients with atrial fibrillation and heart failure in routine practice. Heart Rhythm. 2020; 17: 1057-65.
46. Reant P, Lafitte S, Jaïs P, et al. Reverse remodeling of the left cardiac chambers after catheter ablation after 1 year in a series of patients with isolated atrial fibrillation. Circulation. 2005; 112: 2896-903.
